Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHRA DES warning issued

This article was originally published in The Gray Sheet

Executive Summary

J&J/Cordis' Cypher drug-eluting stent "must be fully deployed and in contact with the target vessel wall," according to a Sept. 1 1Medical Device Alert issued by the UK's Medicines & Healthcare products Regulatory Agency. Three thrombotic events in the UK have been reported to Cordis out of about 9,000 stents implanted since the device became available in Europe in April 2002, the alert notes. Worldwide, 142 instances of thrombosis have been reported from approximately 226,000 Cypher implants, including 117 incidents in the U.S. In July, Cordis sent a "Dear Colleague" letter to physicians warning against over-expansion of the Cypher after 47 instances of sub-acute thrombosis were reported (2"The Gray Sheet" July 14, 2003, p. 9)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel